和铂医药与正大天晴达成战略合作 共同开发和商业化创新型抗体药物

聚焦免疫与肿瘤免疫领域全新抗体药物开发的全球化合作

Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover，Develop and Commercialize Innovative Biologics

Global collaboration focused on new antibody treatments in the fields of oncology and immunology. 

(*Please scroll down for English version)

中国上海，美国马塞诸塞州剑桥，荷兰鹿特丹

2019年5月6日

和铂医药与正大天晴药业集团股份有限公司（以下简称“正大天晴”）今日共同宣布，双方已正式签署产品开发战略合作协议，将在肿瘤免疫及免疫性疾病领域开展创新型抗体药物的开发及商业化合作。

根据此次战略合作协议，双方将发挥和铂医药和正大天晴抗体开发的能力，包括使用和铂医药拥有自主知识产权的全人源转基因小鼠平台,以及正大天晴临床前药物开发的丰富资源，合力推进创新型全人源抗体药物的发现。双方将在各自负责的地区就合作产生的候选药物进行临床开发及商业化运作。正大天晴将拥有中国以及欧洲地区的产品及商业化权益，而和铂医药将拥有全球其他地区，包括美国、日本等地的产品及商业化权益。双方将根据各自商业化区域获得的收益，分享基于净销售收入的提成。其他财务条款尚未被披露。

“此次与正大天晴的合作，是和铂医药通过与合作伙伴共同开发和商业化，打造强大的全球产品管线的重要一步。”和铂医药创始人，董事长兼首席执行官王劲松博士表示，“正大天晴作为一家在创新型肿瘤和免疫治疗领域有着战略布局的制药企业，是我们强有力的合作伙伴。我们期待双方的合作能早日取得预期成果。”针对此次合作，双方将共同拥有所开发的新产品的知识产权、研发及商业化权益。

 “正大天晴致力于开发满足临床需求的新药，此次与和铂医药的合作不仅契合正大天晴创新生物药开发的战略，还标志着正大天晴着力加强创新生物药研发能力的巨大进步。”正大天晴药业集团王善春总裁表示。目前正大天晴已有包括PD-L1抗体在内的数个单抗药物进入二、三期临床开发阶段。

关于和铂医药

和铂医药是一家聚焦于免疫性疾病（包括免疫与肿瘤免疫）领域的全球化的生物制药公司，目前已有多个创新药物进入临床开发阶段，最快的已进入临床二期。公司利用其拥有全球专利的两个全人源抗体转基因小鼠平台（Harbour Mice™）研发针对肿瘤和免疫性疾病的突破性创新疗法。和铂医药还通过与业务伙伴的多元化合作快速拓展其新药研发管线。更多信息，请访问 www.harbourbiomed.com。

关于正大天晴

正大天晴药业集团股份有限公司是集科研、生产和销售为一体的创新型制药集团企业，是国内知名的肝病药物、肿瘤药物的研发和生产基地，为国家重点高新技术企，2017年位列中国医药工业百强企业榜第17位（由中国医药工业信息中心评选发布）。正大天晴始终将科技创新作为企业发展的重要源泉，是国内科研创新能力领先的药企之一。正大天晴每年研发费用投入已超过10亿元，拥有研发人员1000余名，在研项目180多个，其中一类新药30多个，生物药20多个。更多信息，请访问 https://www.cttq.com。

联系方式

周思翔

和铂医药亚太区商务拓展及对外合作高级总监

邮箱：[e-mail]

Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. Announce Strategic Alliance to Discover，Develop and Commercialize Innovative Biologics

Global collaboration focused on new antibody treatments in the fields of oncology and immunology. 

Cambridge, MA, Rotterdam, NL, Shanghai, CN
May 06, 2019 

Harbour BioMed and Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) today announced entering into astrategic alliance to discover, develop and commercialize next-generation biologicsfor multiple therapeutic targets in oncology and immunology.

The collaboration will combine Harbour BioMed's discovery capabilities, including its transgenic mouse technologies for generating fully human antibodies, with CTTQ’s preclinical development resources and expertise. The companies will be responsible for clinical development and commercialization of the rapeutic candidates emerging from the collaboration in their respective regions. Harbour BioMed will be responsible for the United States, Japan, and the rest of the world outside,while CTTQ will have responsibility for Greater China and Europe. The companies will pay royalties to each other based on sales in their respective territories. Additional financial terms were not disclosed.

“The agreement with CTTQ, is part of our strategy to build a robust therapeutic pipeline for global markets through co-discovery, development and commercialization partnerships that capitalize on our patented platforms for generating fully human antibodies,”  said Dr. Jingsong Wang, Founder,Chairman and CEO of Harbour BioMed. “CTTQ, a well-known pharmaceutical company that is making strategic investments in therapeutic innovation in oncology and immunology, is a strong partner in that effort and directly complements our internal discovery programs.” added Dr. Wang. It is expected that both sides will jointly own the IP and development and commercialization rights for the new drugs coming out of this collaboration. 

"CTTQ will be committed to bring valuable treatment agents for diseases with unmet need. The collaboration with Harbour BioMed is well aligned with CTTQ’s strategy for innovative biological medicine development, it also marks significant progress to strengthen our capability of R&D of innovative therapeutic antibodies." said Shanchun Wang, President of CTTQ. CTTQ currently has several monoclonal antibody drugs, includinga PD-L1 inhibitor, which have progressed into Phase 2 and Phase 3 clinical development.

About Harbour BioMed

Harbour BioMed is aglobal biopharmaceutical company developing innovative therapies for cancer andimmune diseases. The company has a growing clinical portfolio and an emergingpipeline of next generation biologics based on its two, patented transgenicmouse platforms (Harbour Mice™) for producingfully human antibodies.

For more information,please visit www.harbourbiomed.com.

About CTTQ

Chia Tai Tianqing Pharmaceutical Group Ltd. (CTTQ) is an integrated pharmaceutical company that engages in drug R&D, manufacturing, marketing,and sales. It is well-known for its leading position in liver disease and oncology therapeutic areas in China, and was honored as one of the leading companies ranked 17th on the list of the “Top 100 Pharmaceutical Enterprises in China” in 2017. CTTQ always regards technological innovation as an important source of enterprise development and is one of the successful pharmaceutical companies with researchand innovation capabilities in China. CTTQ invests more than 1 billion RMB in R&D annually in recent years. It has more than 1,000 employees in R & D and more than 180 projects in its pipeline, including more than 30 innovative small molecular drugs and more than 20 biologics.

For more information, please visit https://www.cttq.com

扫一扫，关注和铂

推 荐 阅 读

▼

欢迎联系我们！电邮：[e-mail]；微信：27674131